Context Capital Management’s AEON Biopharma AEON Stock Holding History

Context Capital Management’s Portfolio AEON Stock Details AEON Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q1	–	Sell	-689	Closed	-$498K	–	341
2022 Q4	$498K	Hold	689	–	–	0.04%	223
2022 Q3	$489K	Hold	689	–	–	0.03%	334
2022 Q2	$487K	Hold	689	–	–	0.03%	354
2022 Q1	$485K	Buy	+689	New	+$483K	0.03%	396

Other funds holding AEON

SCM

Saba Capital Management New York $3.62B AUM 13% 1-Year Est. Return

GCL

Glazer Capital LLC New York $4.71B AUM 81.93% 1-Year Est. Return

FTCM

Fir Tree Capital Management New York $21.8M AUM 1.61% 1-Year Est. Return

ECP

Empyrean Capital Partners Los Angeles, California $3.07B AUM 34.24% 1-Year Est. Return

TCM

Tenor Capital Management New York $6.49B AUM 3.01% 1-Year Est. Return

Periscope Capital Toronto, Ontario, Canada $902M AUM 6.51% 1-Year Est. Return

SIM

Sandia Investment Management Boston, Massachusetts $40.1M AUM 14.58% 1-Year Est. Return

CCA

Castle Creek Arbitrage Avon, Colorado $425M AUM 7.4% 1-Year Est. Return

SCM

Shaolin Capital Management Miami, Florida $2.71B AUM 64.83% 1-Year Est. Return

GCWM

Graham Capital Wealth Management Washington D.c., District of Columbia $113M AUM 11.26% 1-Year Est. Return

Context Capital Management's AEON Position: Q1 2023 in Review

Context Capital Management sold out of AEON Biopharma (AEON) in Q1 2023, closing a stake of 689 shares — an estimated $498K sold.

Context Capital Management first reported a position in AEON in Q1 2022 and held it in 4 quarters. The position peaked at $498K in Q4 2022. 21 funds tracked by Wall St. Rank hold AEON as of Q1 2023.

Context Capital Management reported no remaining AEON Biopharma position as of Q1 2023 after selling out during the quarter.
Context Capital Management sold 689 AEON Biopharma shares in Q1 2023, an estimated $498K.
Context Capital Management first reported a position in AEON Biopharma in Q1 2022 and held it in 4 quarters.
Context Capital Management's AEON Biopharma position peaked at $498K in Q4 2022.
21 funds tracked by Wall St. Rank held AEON Biopharma as of Q1 2023.

Based on Context Capital Management's 13F filing for Q1 2023, filed 8 May 2023.